Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 17/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20931525 | 1.00 | MAPK1 (0.48) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL30554325 | 1.00 | MAPK1 (0.48) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL20931757 | 0.91 | MAPK1 (0.55) | MAPK1MAPK3 | |
| SCHEMBL30554335 | 0.91 | MAPK1 (0.55) | MAPK1MAPK3 | |
| SCHEMBL22284218 | 0.91 | MAPK1 (0.55) | MAPK1MAPK3 | |
| SCHEMBL20931407 | 0.90 | MAPK1 (0.59) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL30554283 | 0.90 | MAPK1 (0.59) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL20916798 | 0.90 | MAPK1 (0.59) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL20920102 | 0.89 | MAPK1 (0.49) | MAPK1MAPK3PAK4CDK2 | |
| SCHEMBL30554370 | 0.89 | MAPK1 (0.49) | MAPK1MAPK3PAK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112020357-B | Salt of indazolyl-containing tricyclic derivative and crystal form thereof | 上海翰森生物医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-110546150-B | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-112020357-A | Salts of indazolyl-containing tricyclic derivatives and crystal forms thereof | 上海翰森生物医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| CN-110546150-A | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2019-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | MAPK1 1/4885MAPK3 14/4885PAK4 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.